GlassScriptPhysician profile
Nicholas Scanlon
NPI 1477084606
$4,287.09
in general payments reported to CMS, 2019-2025
18 companies · $277 in 2025
The $277 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $928 · 2022: $1,854 · 2023: $1,033 · 2024: $196 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,505.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $1,153.32 | 2022-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $425.65 | 2021-2022 | |
| Genzyme Corporation | $372.51 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $320.35 | 2021-2023 | Tezspire |
| Biocryst US Sales Co., LLC | $274.33 | 2021-2023 | Orladeyo |
| Glaxosmithkline, LLC. | $273.89 | 2021-2023 | Nucala |
| Alk-Abello, INC | $216.02 | 2023-2025 | Odactra |
| Pharming Healthcare, INC. | $206.04 | 2021-2022 | |
| Regeneron Pharmaceuticals, INC. | $160.08 | 2022-2023 | Dupixent |
| Incyte Corporation | $146.53 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.11 | 2022 | |
| Pfizer INC. | $106.98 | 2022 | |
| Viiv Healthcare Company | $106.19 | 2022 | |
| Abbvie INC. | $100.64 | 2022 | |
| Genentech USA, INC. | $93.34 | 2023 | Xolair |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $93.07 | 2021 | |
| Horizon Therapeutics Plc | $81.99 | 2022 | |
| Kaleo, INC. | $19.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Scanlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.